$0.03
(Market cap
$83 Mln
Recently Viewed
Clear AllMarket cap
$83 Mln
Revenue (TTM)
$192 Mln
P/E Ratio
3
P/B Ratio
3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
3
Debt to Equity
-1.9
Book Value
$--
EPS
$0.7
Face value
--
Shares outstanding
32,046,352
CFO
$103.23 Mln
EBITDA
$80.55 Mln
Net Profit
$87.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
biote Corp (BTMD)
| -13.7 | 46.7 | -2.0 | -34.2 | -28.3 | -- | -- |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
biote Corp (BTMD)
| -57.9 | 24.9 | 32.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
biote Corp (BTMD)
|
2.2 | 82.7 | 192.2 | 27.1 | 18.5 | -32.9 | 3 | 3.0 |
| 1.1 | 108.1 | 376.9 | -103.4 | -16.8 | -66.2 | -- | 0.9 | |
| 52.8 | 1,389.7 | 767.0 | 32.4 | 7.4 | 7.9 | 42.4 | 3.7 | |
| 17.5 | 43.1 | 328.1 | 5.6 | 20.4 | -46.4 | 7.4 | 7.0 | |
| 468.7 | 76,080.6 | 7,718.0 | 2,459.0 | 44.2 | 64.5 | 31.2 | 18.8 | |
| 185.7 | 7,294.5 | 2,445.5 | 374.2 | 22.0 | 26.3 | 20.4 | 5.7 | |
| 608.1 | 41,773.7 | 3,134.5 | 1,202.3 | 54.4 | -66.9 | 36.2 | 37.6 | |
| 1.8 | 202.1 | 93.2 | -4.2 | 0.0 | -5.5 | -- | 2.7 | |
| 448.0 | 130,512.9 | 15,336.0 | 4,471.0 | 42.5 | 13.9 | 29.8 | 4.1 | |
| 35.4 | 331.3 | 33.8 | 22.0 | 14.3 | 20.9 | 15.1 | 3.1 |
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing... hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas. Read more
Executive Chairman
Mr. Marc D. Beer
Executive Chairman
Mr. Marc D. Beer
Headquarters
Irving, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of biote Corp (BTMD) is $2.25 (NASDAQ) as of 22-Apr-2026 15:36 EDT. biote Corp (BTMD) has given a return of -28.3% in the last 3 years.
The P/E ratio of biote Corp (BTMD) is 3.00 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
3.56
|
-1.64
|
|
2024
|
66.56
|
-1.98
|
|
2023
|
38.73
|
-4.37
|
|
2022
|
-30.79
|
-0.67
|
|
2021
|
--
|
--
|
The 52-week high and low of biote Corp (BTMD) are Rs 4.75 and Rs 1.27 as of 23-Apr-2026.
biote Corp (BTMD) has a market capitalisation of $ 83 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in biote Corp (BTMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.